



Idera Pharmaceuticals to Present at the 2012 BIO International Convention

June 15, 2012 12:30 PM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 15, 2012-- Idera Pharmaceuticals, (NASDAQ: IDRA) a biotechnology company developing novel therapeutics for autoimmune diseases and vaccine adjuvants, today announced that members of the management team will be presenting at the 2012 BIO International Convention at the Boston Convention and Exhibition Center in Boston, MA. The presentation will be made during the BIO Business forum EST in the Celtics Room (104C) on Wednesday, on June 20th, 2012 at 10:30am.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has clinical development programs in autoimmune diseases and cancer. Additionally, Idera has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants. The Company is also advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. For more information, visit <http://www.iderapharma.com>.

Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com